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Levetiracetam, trade name Keppra, is a new second generation antiepileptic drug that is
being increasingly used in brain tumor patients. In patients suffering with brain tumors,
seizures are one of the leading neurologic complications being seen in more than 30% of
patients. Unlike other antiepileptic drugs, levetiracetam is proposed to bind to a synaptic
vesicle protein inhibiting calcium release. Brain tumor patients are frequently on chemother-
apy or other drugs that induce cytochrome P450, causing significant drug interactions.
However, levetiracetam does not induce the P450 system and does not exhibit any rele-
vant drug interactions. Intravenous delivery is as bioavailable as the oral medication allowing
it to be used in emergency situations. Levetiracetam is an attractive option for brain tumor
patients suffering from seizures, but also can be used prophylactically in patients with
brain tumors, or patients undergoing neurological surgery. Emerging studies have also
demonstrated that levetiracetam can increase the sensitivity of Glioblastoma tumors to
the chemotherapy drug temozolomide. Levetiracetam is a safe alternative to conventional
antiepileptic drugs and an emerging tool for brain tumor patients combating seizures.
Keywords: intravenous levetiracetam, seizures, brain tumor patients, antiepileptic drugs, neurologic complications
INTRODUCTION
Individuals with brain tumors represent a very challenging patient
population for clinicians. Not only must clinicians deal with and
treat the primary tumor, but they must also manage the numer-
ous accompanying sequelae. Seizures are commonly seen in brain
tumor patients, with reports of 30% or more depending on the
type of tumor (1). In fact, an epileptic seizure is the presenting
symptom of a tumor in 30–50% of patients, and 10–30% of those
patients will go on to develop recurrent seizures over the course
of the disease (2, 3). The presence of seizures and convulsions has
been shown to add substantial morbidity to these patients (4).
ROLE OF ANTICONVULSANTS IN ACUTE SEIZURE
MANAGEMENT AND SEIZURE PROPHYLAXIS IN BRAIN
TUMOR PATIENTS
Current consensus states that all patients with brain tumors should
be treated with antiepileptic drugs. Currently, the first-line med-
ications including phenytoin, carbamazepine, or valproate all have
demonstrated major side-effects and dangerous drug interactions
with commonly used chemotherapy and tumor medications. The
most common side-effects seen with these highly used antiepilep-
tic medications include cognitive impairment, bone-marrow sup-
pression, liver dysfunction, and dermatological symptoms (5).
Reinforcing the complexity of care in these cases are several stud-
ies demonstrating that side-effects are more frequent in patients
with brain tumors compared with the overall epileptic population
(3, 6). Tsai et al. conducted a retrospective chart review to assess
the effect of valproic acid (VPA) on the outcome of patients with
glioblastoma multiforme (GBM). The electronic medical records
were queried from January 2004 to December 2006 and 102
patients newly diagnosed with GBM were found. Those patients
were followed until January 2010 and over that time 87 patients
died due to disease progression, 7 patients lived and were followed
between 43.4 and 61.0 months, and 8 patients were lost to follow
up. VPA was administered at a starting dose of 400 mg every 8 h in
the form of a sodium salt. It was then adjusted as needed to serum
level or seizure activity. Patients were analyzed in two groups: an
“early” treatment group in which the patients began VPA treat-
ment within 2 weeks of initial diagnosis and the “late” treatment
group where the patients began treatment with VPA more than
2 weeks after initial diagnosis.
Seven patients on VPA therapy provided tissue samples from
a second resection procedure for analysis of histone acetylation.
When these samples were analyzed, there was an increase in acety-
lation in a small subset of patients. Eighty-five of 102 patients
(83.3%) underwent radiotherapy, 61/102 patients (59.8%) under-
went chemotherapy,and all patients had a neurosurgical procedure
with the most common being total excision (47.1%). Thirty-
three of 102 patients had VPA therapy and of those 16 patients
(58.5 serum concentration) started therapy less than a week after
diagnosis and 17 patients (52.4 serum concentration). The early
treatment group had an average serum VPA level of 58.46µg/ml
(34.1–72.6) and the late group was 52.37µg/ml (36.3–73.2). When
the early treatment group was evaluated with univariate analy-
sis there appeared to be a survival benefit conferred (P = 0.035).
However, when a stratified analysis according to chemotherapy
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was used, VPA therapy was not associated with a statistically sig-
nificant difference (P = 0.315) in overall survival. Mild nausea and
thrombocytopenia were the most commonly reported side effect
(11/33 and 11/33, respectively). The authors concluded that VPA
therapy did not affect patient survival significantly (7).
Drug interactions between antiepileptic drugs and commonly
used tumor therapies can lead to inadequate control of the seizures
or sub-therapeutic treatment of the tumor. Toxic effects have
also been noted, leading to unnecessary morbidity. Many of the
common antiepileptic drugs induce cytochrome P450 enzymes
which cause faster metabolism and lower concentrations within
plasma (5). Corticosteroids and many other chemotherapy drugs
exhibit decreased effectiveness in the presence of enzyme activat-
ing antiepileptic drugs (8, 9). The reciprocal relationship is also
seen as there are chemotherapeutic agents that induce enzymes of
the P450 system, lowering concentrations of antiepileptic drugs
(3, 10).
Within the past 10 years, several new antiepileptic drugs includ-
ing lamotrigine, levetiracetam, oxcarbazepine, lacosamide, topira-
mate, and zonisamide have emerged that are without clinically
relevant drug interactions (11–13). Data are limited for these
newer agents and the main limitation in use is lack of intravenous
formulation. Maschio et al. studied the effects of 12 months of
oxcarbazepine (OXC) monotherapy on seizure control in patients
with brain tumor-related epilepsy (BTRE) in a prospective, obser-
vational study. Eleven women and 14 men (mean age 49.7 years,
range 25–75) with BTRE were enrolled between September 2007
and January 2009. Enrolled subjects had a histological diagno-
sis of meningiomas, primary grade I gliomas, low grade gliomas,
anaplastic gliomas, or multiform glioblastoma. Epileptic patients
were eligible if they had simple or complex seizures with or with-
out secondary generalization, if they had greater than or equal
to two seizures per month on no AEDs before referral to their
center, or patients that had been treated at the maximum tolerated
dosage with other AEDs. Twenty-four patients received monother-
apy with OXC of which 17 patients were de novo and 7 patients
rare on monotherapy with one AED. A baseline was established at
the first visit of seizure frequency, neurological examination, Zung
self-depression rating scale (ZSDRS), adverse events profile, and
patients were given a seizure diary. During week one OXC began
and any prior AED was tapered gradually over the first 3 weeks.
The OXC dose started at 300 mg/day and was titrated every 4 days
by 300 mg/day up to 2,100 mg/day over 4 weeks.
The mean follow up duration was 7.1 months (range 1–
12 months). Five patients died as a result of tumor progression
and 10 patients dropped out due to severe side-effects (N = 6),
uncontrolled seizures (N = 3), and a lung complication (N = 1).
Six patients (24%) had severe side-effects due to rash (N = 4),
confusion (N = 1), and dizziness (N = 1) and one patient (4%)
had a mild rash. Four patients had no systemic therapy, 1 had
radiotherapy, 4 had chemotherapy, and 16 had both radiother-
apy and chemotherapy. Patients received a mean OXC dosage
of 1,230 mg/day (range 600–2,100 mg/day). Of the 10 patients
who completed the 12 months of follow up, there was a signif-
icant seizure reduction (P = 0.005) in the mean weekly seizure
number from 2.62± 6.35 at baseline to 0.13± 0.37 in the final fol-
low up. There was a significant difference in the seizure freedom
rate (P = 0.002) by the McNemar’s test between the baseline and
final follow up intent to treat population. Using logistic regres-
sion analysis, the authors found that the efficacy of OXC in
seizure control was not affected by chemotherapy and radiother-
apy (P = 0.658). The ZSDRS showed significantly increased mood
in patients in the final follow up (P = 0.011). Thus, the researchers
concluded that OXC was efficacious in controlling seizures. How-
ever, lack of intravenous formulation limits its use in acute cases.
The other agent used is lamotrigine which is also not available in
intravenous formulation (14).
Meyer et al. conducted a prospective study in order to deter-
mine the protein binding and distribution of LTG in serum, brain
tissue, and brain tumor in three female and eight male subjects
with brain tumors. From 1994 to 1996, 11 patients had neurosur-
gical operations for benign tumors (N = 2) and malignant tumors
(N = 9). The subjects were aged 33–68 years (mean 56 years).
Patients were enrolled if in the days immediately preceding neuro-
surgery they showed signs of seizures or if their preoperative EEG
showed symptoms of epilepsy. For intraoperative and postoper-
ative seizure control, subjects were administered LTG with PHT
in seven patients or LTG with PHT and CBZ in three patients.
Patients received a mean of 54.4 days of preoperative treatment
(range 1 day–17 months) with LTG, and 2 h preoperatively were
given a dose of 100–200 mg/day in addition to PHT or PHT
and CBZ. After administration, serial blood samples were taken
from 0.5 to 12.5 h, as well as an intraoperative blood sample and
intraoperative removed tumor tissue (N = 6). HPLC was used to
assay LTG concentrations and an ultrafiltration system was used
to determine plasma binding of LTG.
The LTG concentration at the time of tumor sectioning was
on average 3.7µg/ml (range 1.1–9.8) in the serum, an average
of 6.8µg/g (range 1.0–14.9) in the brain tissue, and an average
of 4.4µg/g (range 2.0–8.3) in the tumor tissue. The resultant
brain/serum ratio was 2.8 and the tumor/serum ratio was 1.9.
The protein binding of LTG was determined to be a lipophile AED.
The researchers concluded that LTG penetrates well into brain and
tumor tissue and had a moderately high protein binding (15). It
has been shown that pregabalin has been used as adjunctive ther-
apy in this subgroup of patients although limited data are available,
which is the case with most other newer agents (16).
Lacosamide is one of the newest agents which has the advantage
of being available in both an oral and intravenous formulation.
Few studies reported the efficacy as an adjunctive agent, and data
are limited at this time.
Saria et al. conducted a retrospective chart review to study the
use of lacosamide in patients with brain tumors. Seventy patients
with primary brain tumors who received lacosamide for seizure
control were identified by reviewing the medical records of five
United States medical centers with brain tumor programs. Primary
tumors included glioblastoma (40%), grade II gliomas (36%),
and were followed by grade III anaplastic astrocytomas, anaplas-
tic/atypical meningiomas, anaplastic ependymomas, and pleo-
morphic xanthoastrocytomas. Seventy-eight percent of patients
(N = 55) had partial seizures and 17% had of patients (N = 12)
had generalized seizures. Subjects had a mean age of 51 years of
age. Eighty-four percent of patients had chemotherapy (N = 59)
and 81% had radiation therapy (N = 57). The majority of patients
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had a surgical procedure performed, including 63% had a cran-
iotomy, 23% had a biopsy, and 14% had both. Most patients (83%)
were on an additional AED as well as lacosamide, which was most
commonly levetiracetam. The cause for the addition of lacosamide
therapy was most commonly recurrent seizures (74%) or toxicity
from another AED (23%).
A decrease in seizure frequency was found in 46 patients (66%)
and seizure control remained unchanged in 21 patients (30%).
A greater than 50% decrease in seizure frequency was achieved
in 38 patients (83%). No medication toxicities were reported in
77% of patients (N = 54) receiving lacosamide. The most com-
mon toxicity reported was fatigue noted by four subjects (6%).
The researchers concluded that in patients with brain tumors
lacosamide was well tolerated and an active add-on AED (17).
Maschio et al. also conducted a case series of 14 patients
with BTRE that had not obtained adequate seizure control on
other AED treatment. Patients were consecutively recruited if they
had at least one seizure per month prior to study recruitment.
Lacosamide was the first-fifth add-on AED therapy and was started
at 100 mg/day and titrated weekly by 100 mg/day to a maximum
dosage of 400 mg/day.
Follow up occurred in subjects at a mean of 5.4 months
(range< 1–10 months). During this period, nine patients died
from tumor progression,no patients’underwent radiation therapy,
and nine patients underwent chemotherapy. The mean lacosamide
dosage was 332.1 mg/day (range 100–400 mg/day). One subject
dropped out due to dizziness and blurred vision. The mean
seizure frequency at baseline was 15.4 per month and at fol-
low up decreased to 1.9 per month. Subjects had a median
seizure reduction percentage of 79.8%. Five patients (35.7%) had
a greater than 50% seizure reduction and six patients (42.9%)
were seizure free. One patient (7.1%) had an unmodified seizure
frequency. There was a statistically significant difference in the
mean monthly seizure frequency from baseline to follow up
(P = 0.022). The authors concluded that lacosamide is a valid
alternative add-on AED in patients with BTRE (18) have had
seizures.
ROLE OF LEVETIRACETAM IN ACUTE SEIZURE
MANAGEMENT AND SEIZURE PROPHYLAXIS IN BRAIN
TUMOR PATIENTS
In this article we chose to focus on the use of levetiracetam. In our
experience we have witnessed better efficacy and there seems to be
more evidence within the literature supporting levetiracetam in
terms of seizure management. An important point to make here is
that there are many antiepileptic drug choices, but very little com-
parative effectiveness data to help physicians decide the best AED
to use in the innumerably variable clinical scenarios. This paper
attempts to make a contribution and demonstrate what we feel is a
good drug choice for managing seizures in the unique population
of patients with brain tumors. Levetiracetam is very different from
the more commonly used antiepileptic drugs (19, 20). Its action
is believed to involve neuronal binding to synaptic vesicle protein
2A (SV2A). Binding to this protein somehow acts as an inhibitor
of synaptic vesicle exocytosis (21) decreasing presynaptic neuro-
transmitter release (21). The mechanisms of action for the more
commonly used antiepileptic drugs including benzodiazepines
and barbiturates affect gamma-aminobutyric acid potentiation,
calcium channels, or sodium channels (22).
Levetiracetam exhibits a relative bioavailability of 100% follow-
ing both oral (23) and intravenous administration. Levetiracetam,
given intravenously, is considered bioequivalent to oral tablets
and is well tolerated (12). Being able to give this drug intra-
venously is an extremely attractive trait which makes treatment in
emergency or perioperative situations a possibility. Perhaps more
importantly is the fact that levetiracetam is not extensively metab-
olized by the cytochrome P450 system (23). This is in extreme
contrast to the most commonly used antiepileptic drugs. Leve-
tiracetam has not been shown to cause any induction or inhibition
of the other important cytochrome P450 enzymes including uri-
dine diphosphate-glucuronyl-transferase or epoxide hydroxylase
(23). Levetiracetam has repeatedly been shown to exhibit a low
potential for clinically relevant pharmacokinetics both with other
antiepileptic drugs or drugs that could possibly be used to treat
brain tumors (13, 23). Studies have demonstrated no or very few
side-effects with levetiracetam treatment in patients with brain
tumors who also received antineoplastic agents (7, 24–26). A few
of the larger studies were able to report the occasional occurrence
of somnolence with initial doses of levetiracetam (27).
SEIZURE MANAGEMENT WITH LEVETIRACETAM
Over the past 10 years, there have been several studies that looked
at both the effectiveness and safety of using levetiracetam in brain
tumor patients. Levetiracetam, as both an adjunct therapy and
a monotherapy, has shown a complete seizure control rate of
between 47.4 and 100% (7, 25–27). Reductions in seizures by more
than 50% were recorded in a majority of articles within the liter-
ature. These numbers were extremely variable ranging from 29
to 100%. However most of these studies were conducted with
limited numbers of patients and were mostly retrospective analy-
ses (6, 11, 24, 25, 28–32). The two largest studies and the ones
most likely indicative of what clinicians will see in their patients
are from a 2005 Neurology supplement by Stevens et al. (31)
and a report from Rosati et al. (27) in 2010. The study in Neu-
rology reviewed the medical charts of 278 patients with varying
brain tumors treated with levetiracetam over a 36-month period.
They witnessed a greater than 50% reduction in seizure activity
in over 60% of their patients. The second largest study, by Rosati
et al., involved 176 patients in a prospective study over a 3-year
period (27). In this study, 91% of patients were seizure free with
a monotherapy of levetiracetam. Forty-nine of the patients (60%)
experienced fast and long-lasting seizure control with initial doses
of 1,500–3,000 mg/day. In 23 patients (31.5%) an increase in the
dosage up to 3,000–4,000 mg/day was necessary because of sub-
therapeutic drug levels. The authors experienced no relevant lab-
oratory abnormalities (27). Levetiracetam has demonstrated good
potential however; larger cohorts over more extended periods of
time would be useful.
While levetiracetam has demonstrated good potential as an
adjunct therapy as well as monotherapy, several alternative uses
for levetiracetam are currently being explored such as refractory
status epilepticus.
Traditional seizure medications have proven woefully ineffec-
tive with over half of brain tumor patients continuing to have
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seizures despite treatment (32). Status epilepticus is seen in up
to 26% of these cases (6) with the overall mortality rate reach-
ing 30–40% (33). First-line treatment for status epilepticus in
this patient population is a combination of benzodiazepines and
phenytoin (34), which has an efficacy rate of 60–70%. Refractory
status epilepticus requires an additional anesthetic drug such as
propofol or midazolam to induce an iatrogenic coma (35). Recent
data suggest that an alternative combination of phenytoin and lev-
etiracetam has proven to be a very effective cocktail that does not
subject the patient to mechanical ventilation or sedation (35).
Swisher et al. conducted a retrospective chart review of elec-
tronic medical records for all patients with a diagnosis of primary
or metastatic brain tumor who presented with complex partial
refractory status epilepticus and received Trifecta (intravenous
PHT, LEV, and oral PGB). All patients were >18 years of age and
presented between January 2006 and December 2009. Study sub-
jects ages ranged from 25 to 84 with an average age of 56.9. There
was a prior history of seizures in 70% of patients. GBM occurred
in 52% of patients and was the most common tumor type, yet
the tumor locations of all subjects tumors was highly variable.
Ninety-one percent of patients had underwent resection for their
brain tumor. Thirty-nine percent of patients received radiation,
39% received chemotherapy, and within 1 month of RSE onset
52% underwent a biopsy or brain tumor resection. PHT or LEV
was used as first-line therapy in all patients and pregabalin was
typically used as second or third-line therapy. The median dosage
of LEV was 3,000 mg/day and the median dosage of PGB was
375 mg/day.
Ninety-one percent of patients were already on one AED when
RSE was diagnosed, and it was statistically significant (P = 0.03)
that more patients in the responder group were on an AED at
baseline (100 vs. 71%). The average PHT blood level in the Tri-
fecta responder patients was 18.9 at the time of SE cessation. After
the administration of Trifecta 30% of patients’ (7/23) seizure fre-
quencies were unchanged. After the administration of Trifecta,
status epilepticus ceased in 70% of patients (16/23). On average,
24 h after the addition of the third AED status epilepticus was
aborted. There was a zero mortality rate in the responder group
and only one patient in the responder group required intubation.
There were no adverse reactions to Trifecta reported. The authors
concluded that in patients with brain tumors presenting in RSE
that Trifecta use is highly effective and safe (16).
SURGICAL PROPHYLAXIS
Patients with brain tumors often must undergo neurological
surgery for resection or biopsy, which in and of itself can increase
risk of seizures. So controlling seizures in the perioperative phase
of brain tumor management is an important consideration (3, 36).
Bahr et al. performed an open-label, prospective, single-arm
study investigating the use of LEV for perioperative seizure con-
trol in patients with suspected primary brain tumors undergoing
neurosurgery (e.g., biopsy or resection) (36). Inclusion criteria
included age>18 years, neuroradiological imaging suspected pri-
mary brain tumor, and planned biopsy or resection neurosurgical
procedure. Patients were excluded if in the seven preoperative days
any AED other than LEV was used or if there was a known LEV
allergy or previous severe side-effects to LEV. Between January
2008 and June 2009, 25 of 30 study patients were enrolled and
treated for 4 weeks before and 4 weeks after a neurosurgery pro-
cedure with oral and IV LEV. During this time patients had four
scheduled visits for monitoring and data collection. Of the 27
patients who underwent surgery,22 were diagnosed with a primary
brain tumor, 3 with meningioma, 2 with brain metastasis, and 1
with abscess. Subjects were started on an oral dose of LEV 500 mg
twice daily and titrated to 1,000 mg twice daily after 72 h. The
dose was further increased if the patient was at an increased risk of
seizures or had seizures in this period. IV LEV was given immedi-
ately and for 36 h postoperatively before being transitioned back
to oral LEV. Three patients did not have the planned procedure
and two patients were lost to follow up.
In the pre-surgery phase (defined as 3 days–4 weeks prior to
surgery), 100% of patients were seizure free after the initiation of
LEV therapy. In the 48 h post surgery phase and early follow up
phase (defined as 48 h–4 weeks post surgery), the seizure free rates
were 88 and 84%,respectively. Three patients failed LEV treatment,
even after the dose was titrated up to 3,000 mg/day. There were no
serious adverse events reported with LEV treatment. The authors
concluded that oral and IV LEV for perioperative seizure control
was feasible and safe in patients with tumor-related seizures (36).
However, to date only four studies have been able to demonstrate
the effectiveness of levetiracetam in the perioperative phase (32–
35). Zachenhofer et al. (37) retrospectively studied 78 patients with
brain tumors who received between 1,000 and 3,000 mg of LEV
perioperatively. After a mean follow up time of 10.5 months, 91%
of the patients were seizure free. This study demonstrated a very
low seizure frequency of 2.5% in the early postoperative period.
These studies propose both the feasibility and safety of intravenous
levetiracetam in the perioperative treatment, but more long term
trials are needed.
INCREASING CHEMOTHERAPY SENSITIVITY
Levetiracetam’s role in increasing chemotherapy sensitivity is a
fascinating new field of interest. Some antiepileptic drugs have
actually shown that they can inhibit histone deacetylase activ-
ity within the tumor. Histone deacetylase inhibitors can modu-
late temozolomide activity by modulating methylguanine-DNA-
methyltransferase (MGMT) expression (37) thereby allowing for
increased temozolomide efficacy. Levetiracetam has in fact been
shown to increase the transcription of histone deacetylase 1
(HDAC1) which ultimately silences MGMT (38). Levetiracetam
has also been shown to have a neuroprotective role via free-radical
scavenging activity (39), reducing inflammation and neuronal
death (40). All of these attributes may lead to the ability of lev-
etiracetam to prevent radiochemotherapy-caused nerve damage.
Levetiracetam may in fact increase temozolomide-induced cyto-
toxicity in patients with GBM who do express the MGMT protein
while also experiencing little adverse side-effects (41, 42). This
could be a very exciting area of research as GBM tumors are so
common.
CONCLUSION
Brain tumor patients require a multidisciplinary approach involv-
ing the use of chemotherapy, radiation, possible surgery, and
in many cases antiepileptic drugs. The first-line treatments for
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these patients have numerous drug interactions to be weary of
when using them in addition to anticancer drugs. Increased side-
effects have led to renewed interest in antiepileptic drugs that
do not induce cytochrome P450 pathways. Levetiracetam, a drug
unique in both its mechanism of action and in the way that
it does not cause the drug interactions of the first-line drugs,
is among the newer antiepileptic drugs. Several studies have
demonstrated the effectiveness of levetiracetam in the role of
monotherapy as well as adjunct therapy to other antiepileptic
drugs. Levetiracetam has also sparked the interest of clinicians
for its role in surgical prophylaxis, for refractory status epilepti-
cus, and the ability to increase chemotherapy sensitivity. Some of
these attributes have more supporting evidence than others, but
levetiracetam does warrant more testing and could very well be
a promising drug in the fight to control epilepsy in brain tumor
patients.
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